Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?


15:16 Uhr
WDH/Aktien New York Ausblick: Rekordjagd hält - Dow über 20800 Punkten erwartet

Safe Orthopaedics Announces the Suspension and Implementation of a Liquidity Contract

Donnerstag, 01.12.2016 08:05


Regulatory News:

SAFE ORTHOPAEDICS (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments, today announces that on November 30, 2016 it has suspended the liquidity contract entrusted to Invest Securities on February 5, 2015.

At November 30, 2016, the following assets were allocated to the liquidity contract:

• 45,382 Safe Orthopaedics’ shares and

• 28,908.62 euros in cash.

From December 1, 2016 and until the renewal of the authorisation to be put to the vote by shareholders in the Combined General Meeting of January 25, 2017, Kurma Biofunds, a major shareholder and director of Safe Orthopaedics, has arranged for Invest Securities to implement a liquidity contract in accordance with the code of conduct established by AMAFI and approved by a decision of the Autorité des Marchés Financiers on March 21, 2011.

The following assets have been allocated to the liquidity agreement:

• 25,000 Safe Orthopaedics’ shares and

• 20,000 euros in cash

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared. The company is based at Eragny-sur-Oise (France), and has 34 employees.

For more information, visit:

View source version on

(c)Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.